These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33064947)

  • 21. A Novel Bifunctional μOR Agonist and σ
    Miao Z; Zhong Y; Gan Y; Fu K; Liu W; Cao Z; Zhao T; Li Z; Hai A; Peng Y; Zuo Z; Zhang T; Hu S; Chen C; Kang T; Huang T; Guo D; Ke B
    J Med Chem; 2023 Dec; 66(23):16257-16275. PubMed ID: 38015878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform.
    Vasudevan L; Vandeputte M; Deventer M; Wouters E; Cannaert A; Stove CP
    Biochem Pharmacol; 2020 Jul; 177():113910. PubMed ID: 32179045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis, biological, and structural explorations of a series of μ-opioid receptor (MOR) agonists with high G protein signaling bias.
    Yang Y; Wang Y; Zuo A; Li C; Wang W; Jiang W; Zhang X; Che X; Zhang Y; Wu W; Cen X; Wang H; Tian J
    Eur J Med Chem; 2022 Jan; 228():113986. PubMed ID: 34802839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Redoubling the ring size of an endomorphin-2 analog transforms a centrally acting mu-opioid receptor agonist into a pure peripheral analgesic.
    Piekielna J; De Marco R; Gentilucci L; Cerlesi MC; Calo' G; Tömböly C; Artali R; Janecka A
    Biopolymers; 2016 May; 106(3):309-17. PubMed ID: 27038094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias.
    Kennedy NM; Schmid CL; Ross NC; Lovell KM; Yue Z; Chen YT; Cameron MD; Bohn LM; Bannister TD
    J Med Chem; 2018 Oct; 61(19):8895-8907. PubMed ID: 30199635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural Simplification of a Tetrahydroquinoline-Core Peptidomimetic μ-Opioid Receptor (MOR) Agonist/δ-Opioid Receptor (DOR) Antagonist Produces Improved Metabolic Stability.
    Henry SP; Fernandez TJ; Anand JP; Griggs NW; Traynor JR; Mosberg HI
    J Med Chem; 2019 Apr; 62(8):4142-4157. PubMed ID: 30924650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 'Biased' opioids could yield safer pain relief.
    Wadman M
    Science; 2017 Nov; 358(6365):847-848. PubMed ID: 29146784
    [No Abstract]   [Full Text] [Related]  

  • 28. Modulation of peripheral μ-opioid analgesia by σ1 receptors.
    Sánchez-Fernández C; Montilla-García Á; González-Cano R; Nieto FR; Romero L; Artacho-Cordón A; Montes R; Fernández-Pastor B; Merlos M; Baeyens JM; Entrena JM; Cobos EJ
    J Pharmacol Exp Ther; 2014 Jan; 348(1):32-45. PubMed ID: 24155346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligands.
    Bender AM; Griggs NW; Anand JP; Traynor JR; Jutkiewicz EM; Mosberg HI
    ACS Chem Neurosci; 2015 Aug; 6(8):1428-35. PubMed ID: 25938166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sigma-1 receptor modulates neuroinflammation associated with mechanical hypersensitivity and opioid tolerance in a mouse model of osteoarthritis pain.
    Carcolé M; Kummer S; Gonçalves L; Zamanillo D; Merlos M; Dickenson AH; Fernández-Pastor B; Cabañero D; Maldonado R
    Br J Pharmacol; 2019 Oct; 176(20):3939-3955. PubMed ID: 31332781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent and Centrally Acting μ Opioid Analgesic with Reduced Abuse Liability.
    Crowley RS; Riley AP; Sherwood AM; Groer CE; Shivaperumal N; Biscaia M; Paton K; Schneider S; Provasi D; Kivell BM; Filizola M; Prisinzano TE
    J Med Chem; 2016 Dec; 59(24):11027-11038. PubMed ID: 27958743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and Biological Characterization of Cyclic Disulfide-Containing Peptide Analogs of the Multifunctional Opioid/Neuropeptide FF Receptor Agonists That Produce Long-Lasting and Nontolerant Antinociception.
    Zhang M; Xu B; Li N; Liu H; Shi X; Zhang Q; Shi Y; Xu K; Xiao J; Chen D; Zhu H; Sun Y; Zhang T; Zhang R; Fang Q
    J Med Chem; 2020 Dec; 63(24):15709-15725. PubMed ID: 33271020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
    Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
    Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis, Biological, and Structural Explorations of New Zwitterionic Derivatives of 14- O-Methyloxymorphone, as Potent μ/δ Opioid Agonists and Peripherally Selective Antinociceptives.
    Spetea M; Rief SB; Haddou TB; Fink M; Kristeva E; Mittendorfer H; Haas S; Hummer N; Follia V; Guerrieri E; Asim MF; Sturm S; Schmidhammer H
    J Med Chem; 2019 Jan; 62(2):641-653. PubMed ID: 30571123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted Mu opioid agonist with antihyperalgesic activity: II. In vivo pharmacological characterization in the rat.
    Whiteside GT; Harrison JE; Pearson MS; Chen Z; Fundytus ME; Rotshteyn Y; Turchin PI; Pomonis JD; Mark L; Walker K; Broglé KC
    J Pharmacol Exp Ther; 2004 Aug; 310(2):793-9. PubMed ID: 15054116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties.
    Valenzano KJ; Miller W; Chen Z; Shan S; Crumley G; Victory SF; Davies E; Huang JC; Allie N; Nolan SJ; Rotshteyn Y; Kyle DJ; Broglé K
    J Pharmacol Exp Ther; 2004 Aug; 310(2):783-92. PubMed ID: 15054115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A bifunctional-biased mu-opioid agonist-neuropeptide FF receptor antagonist as analgesic with improved acute and chronic side effects.
    Drieu la Rochelle A; Guillemyn K; Dumitrascuta M; Martin C; Utard V; Quillet R; Schneider S; Daubeuf F; Willemse T; Mampuys P; Maes BUW; Frossard N; Bihel F; Spetea M; Simonin F; Ballet S
    Pain; 2018 Sep; 159(9):1705-1718. PubMed ID: 29708942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of 5-substituted tetrahydronaphthalen-2yl-methyl with N-phenyl-N-(piperidin-4-yl)propionamide derivatives as potent opioid receptor ligands.
    Deekonda S; Wugalter L; Kulkarni V; Rankin D; Largent-Milnes TM; Davis P; Bassirirad NM; Lai J; Vanderah TW; Porreca F; Hruby VJ
    Bioorg Med Chem; 2015 Sep; 23(18):6185-94. PubMed ID: 26299827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists.
    Grenald SA; Young MA; Wang Y; Ossipov MH; Ibrahim MM; Largent-Milnes TM; Vanderah TW
    Neuropharmacology; 2017 Apr; 116():59-70. PubMed ID: 28007501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats.
    Schwienteck KL; Faunce KE; Rice KC; Obeng S; Zhang Y; Blough BE; Grim TW; Negus SS; Banks ML
    Neuropharmacology; 2019 May; 150():200-209. PubMed ID: 30660628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.